Amgen Inc (AMGN) 161.78 $AMGN Midday Glance:

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 1:31 PM

Amgen Inc (AMGN) 161.78 $AMGN

Midday Glance: Biotechnology companies
AP - 11 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)

Cramer: 'Remarkable' Data from Regeneron, Amgen; Sees Edward Lifesciences Going Higher
at The Street - 2 hrs 26 mins ago
TheStreet's Jim Cramer analyzes Regeneron and Amgen's promising cholesterol drugs, to Mobileye's secondary offering and Oppenheimer's downgrade of Garmin.
GRMN: 48.30 (+0.30), EW: 147.63 (+12.28), AMGN: 161.78 (+7.52), MBLY: 42.09 (+0.46), REGN: 446.44 (+17.06)

Early Glance: Biotechnology companies
AP - 2 hrs 56 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)

Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), AMGN: 161.78 (+7.52)

Regeneron's alirocumab shows durable effect in lowering "bad" cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT

AMGN: 161.78 (+7.52), SNY: 48.70 (+1.63), REGN: 446.44 (+17.06)

1 Expensive Biotech Stock Worth Buying
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 15, 10:01AM CDT
Source: Ligand Pharmaceuticals Why buy something that's expensive? There are multiple answers to this question, of course. I'd contend that the best response of all is that it makes sense to buy an expensive item if its value is likely to...
AMGN: 161.78 (+7.52), LGND: 75.17 (+0.18), GSK: 46.91 (+0.54)

Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha(TM) (evolocumab) In The New England Journal of Medicine
PR Newswire - Sun Mar 15, 10:00AM CDT
Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha(TM) (evolocumab), a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. These data were presented today at a Late-Breaking Clinical Trial session at the American College of Cardiology's 64th Annual Scientific Session (ACC.15) and published in the New England Journal of Medicine. A two-year analysis of Repatha safety and tolerability data from the longest proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor trial to date (OSLER-1) was also presented.
AMGN: 161.78 (+7.52)

Should Gilead Sciences Inc.’s Slowing Growth Concern Investors?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 15, 7:57AM CDT
The failure of the market to buy into Gilead Sciences ' amazing growth story is a flat-out mystery in the eyes of many investors. Despite growing product sales by an astounding 127% and non-GAAP earnings per share by 297% last year, the stock has...
BIIB: 419.99 (+6.64), ESRX: 83.50 (+2.13), GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), ABBV: 58.93 (+0.93), CELG: 120.02 (+2.29)

Japanese study shows Amgen's evolocumab lowers bad cholesterol in high risk patients
Seeking Alpha - at Seeking Alpha - Sat Mar 14, 8:17PM CDT

AMGN: 161.78 (+7.52)

New Detailed Data From Phase 3 Study Show Amgen's Repatha(TM) (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol
PR Newswire - Sat Mar 14, 11:30AM CDT
Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha(TM) (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol. Data from the study showed subcutaneous Repatha 140 mg every two weeks or 420 mg monthly, compared to placebo, in combination with different daily doses of atorvastatin, reduced low-density lipoprotein cholesterol (LDL-C) by 67 to 76 percent from baseline at week 12 and at the mean of weeks 10 and 12. The data were presented at the American College of Cardiology's 64th Annual Scientific Session (ACC.15).
AMGN: 161.78 (+7.52)

3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 419.99 (+6.64), BBC: 33.77 (+0.32), BIB: 166.75 (+5.88), XBI: 230.59 (+2.16), IBB: 351.70 (+6.37), AMGN: 161.78 (+7.52)

Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 255.72 (+0.74), CLDX: 30.35 (+0.61), EPZM: 22.42 (-0.60), STML: 16.23 (+0.22), JNJ: 100.53 (+1.32), ABBV: 58.93 (+0.93), INFI: 16.05 (+0.59), PTLA: 41.44 (+0.74), INCY: 90.04 (+0.73), PFE: 34.45 (+0.45), IMGN: 7.66 (-0.19), AMGN: 161.78 (+7.52), LLY: 71.13 (+1.24), BMY: 67.86 (+0.99), GSK: 46.91 (+0.54), SGEN: 38.93 (+0.62), GILD: 100.94 (+1.33), KITE: 63.24 (+0.15), MRK: 57.05 (+0.85), TEVA: 60.60 (+0.60), CELGZ: 3.02 (-0.03), KPTI: 30.65 (+2.57), NVS: 97.93 (+0.89)

Amgen Has Been Flat For The Past 4 Months
Abba's Aces - at Seeking Alpha - Fri Mar 13, 8:39AM CDT

AMGN: 161.78 (+7.52)

Patient enrollment complete in trial expansion phase of Cytokinetics' heart drug
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:19AM CDT

CYTK: 7.73 (-0.25), AMGN: 161.78 (+7.52)

Final Glance: Biotechnology companies
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.94 (+1.33), AMGN: 161.78 (+7.52), CELG: 120.02 (+2.29)

Akebia Completes Enrolment in Phase II Renal Anemia Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 3:45PM CDT
Akebia Therapeutics (AKBA) completed enrolment in the third and final cohort of a phase II study on AKB-6548, being evaluated for treating patients with anemia related to chronic kidney disease undergoing dialysis.
LCI: 64.94 (-0.09), AMGN: 161.78 (+7.52), AKBA: 12.86 (-0.38), AMAG: 54.52 (-0.48)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Lick the Plate Hits 2,000 Shows with Clown Band

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...